Diabetes Mellitus. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Salsalate (750 mg tablets) 3 gram, bid, for 12 weeks. Intervention 2: Placebo, 2 similar tablets, bid, for 12 weeks.
Salsalate (750 mg tablets) 3 gram, bid, for 12 weeks
Placebo, 2 similar tablets, bid, for 12 weeks
Sponsors
Isfahan Endocrine and Metabolism Research Center
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: HbA1c>=5% and BS=100mg/dl or BS>=140mg/dl in OGTT) Exclusion criteria: Type 1 DM or past history of DKA, pregnancy/lactation, surgery within 1 month before the trial, known diagnosed malignancy, confirmed peptic ulcer or GI bleeding, diagnosed heart failure (function class 3 or 4), clinical ACS, CVA, TIA, revascularization within 6 month prior to study, uncontrolled hypertension (systolic BP>150 mmHg or diastolic BP>100 mmHg with full dose of 3 drugs) , history of drug abuse or alcohol consumption, history of active hepatitis , psychological disorders , previous allergy to aspirin or NSAIDS , continuous use of NSAIDS , Warfarin, Clopidogrel, Corticosteroid, Macroalbuminuria, chronic tinnitus, Hb500 mg/dl , serum creatinine more than 1.4 in women and more than 1.5 in men or GFR<60.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose. Timepoint: weeks ( 0, 4, 8, 12). Method of measurement: Enzymatic. | — |
Secondary
| Measure | Time frame |
|---|---|
| Insulin resistance. Timepoint: weeks ( 0 , 4 , 8 , 12). Method of measurement: (plasma insulin)(plasma glucose)/22.5=HOMA-IR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElham Faghih Imani
Isfahan Endocrine and Metabolism Research Center
Outcome results
None listed